Trace Neuroscience is focused on advancing the understanding and treatment of neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS). The company employs innovative technologies aimed at developing therapeutic solutions that target the underlying mechanisms of ALS. Their approach includes leveraging advanced research methodologies to identify biomarkers and potential drug candidates, which can lead to more effective treatments for patients suffering from this debilitating condition.

In addition to their research initiatives, Trace Neuroscience emphasizes collaboration with academic institutions and industry partners to enhance their scientific capabilities. The company is committed to translating their findings into practical applications, thereby improving patient outcomes. Their pipeline includes a range of products that are designed to address the complexities of ALS, showcasing their dedication to pioneering new therapies and contributing to the broader field of neuroscience.

United States

Launched in 2024, Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases. With an initial focus on ALS, the company is developing novel therapies to restore UNC13A protein function to re-establish healthy communication between nerves and muscle cells.

Trace Neuroscience

Company Details